Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Expert interview - 13/05/2019 Telemedizin: Vitor Vieira (Inova DE) mit einem selbst entwickelten Wearable, einem T-Shirt zur verbesserten Interaktion zwischen Patienten und Kardiologen für fernkontrolliertes Monitoring

    Innovation management in the life sciences – Inova DE provides insights

    Personalized medicine, medical technology, digital health and artificial intelligence are revolutionizing diagnostics and product development. Analyses are becoming faster and more precise, and data volumes can now be networked and used effectively. The goal of improving people's quality of life is within reach, and this will also strengthen Germany’s future viability. However, not every good idea can be turned into a marketable commodity.…

    https://www.gesundheitsindustrie-bw.de/en/article/news/innovation-management-in-the-life-sciences-inova-de-provides-insights
  • Article - 16/04/2019 20190218_Foto_Labor_Quelle_UniversitNatsklinikum_Heidelberg.jpg

    Tumour monitoring using liquid biopsy

    Liquid biopsy, the analysis of cancer biomarkers and circulating tumour cells in body fluids such as blood, is revolutionising the diagnosis and monitoring of cancer. It has also been possible to expand circulating tumour cells from the blood under laboratory conditions. It is expected that in the future, liquid biopsy will be able to precisely characterise tumour cells at every stage of a cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/tumour-monitoring-using-liquid-biopsy
  • Article - 28/03/2019 The IT expert sitting at a meeting table.

    Supporting the human use of artificial intelligence

    Artificial intelligence is no longer a vision of the future, but is already in our midst: whether it is parking aids or search engines, we use the technology quite naturally in many areas of daily life. It promises new, unlimited opportunities, but also poses risks. Experts from the Integrata Foundation in Tübingen work on ethical issues and the human use of IT for improving the life of as many people as possible.

    https://www.gesundheitsindustrie-bw.de/en/article/news/supporting-the-human-use-of-artificial-intelligence
  • Article - 22/03/2019 Prof. Lichter (left) and Prof. Schneeweiss, who run the Translational Breast Cancer Programme in Heidelberg, in the laboratory

    Personalised therapies for treating metastasing breast cancer

    Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements.

    https://www.gesundheitsindustrie-bw.de/en/article/news/personalisierte-therapieansaetze-bei-metastasiertem-brustkrebs
  • Article - 07/02/2019 Ein Porträtfoto des Mediziners.

    Artificial intelligence in ophthalmology

    Retinal diseases such as age-related macular degeneration (AMD) are now treatable. However, it is hard to predict individual disease progression. A group of researchers at the University Eye Centre in Freiburg are currently developing a new system which is hoped will allay fears and improve therapy planning. The system uses artificial intelligence to predict therapeutic outcome from image and patient data. Initial results are already available.

    https://www.gesundheitsindustrie-bw.de/en/article/news/artificial-intelligence-in-ophthalmology
  • Article - 29/01/2019 RNA segments shown in black/grey, which are processed by grey and blue (represented as spheres) enzyme complexes.

    Targeted RNA editing with the body’s own enzyme activity

    Completely new possibilities for research and gene therapy became available following the development of the CRISPR/Cas method for targeted modification of the genome. However, treatment with molecular scissors is not without risk as potential errors are stored in the genome forever. Scientists from Tübingen have developed an alternative method in which the intervention takes place at the RNA level using the body's own enzymes and is thus…

    https://www.gesundheitsindustrie-bw.de/en/article/news/targeted-rna-editing-with-the-bodys-own-enzyme-activity
  • Press release - 28/01/2019 21359_de.jpg

    5,5 millions for project on smart matrices for knee cartilage repair

    A research project in cartilage regeneration, in which the Institute of Orthopaedic Research and Biomechanics at Ulm University participates together with partners from eight european countries, was recently financed by the European Commission with 5.5 million Euro. Named RESTORE, the project aims to create 3D matrices incorporating smart nanomaterials to repair knee cartilage lesions thereby reducing or delaying the onset of osteoarthritis,…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/55-millions-for-project-on-smart-matrices-for-knee-cartilage-repair
  • Article - 10/01/2019 Cover of the fourth gene technology report.

    Stocktaking and recommendations for action: the BBAW’s fourth gene technology report

    In the new gene technology report, the interdisciplinary working group of the Berlin-Brandenburg Academy of Sciences (BBAW) takes stock of gene technology developments in Germany during the past few decades, and discusses the societal, legal and ethical challenges associated with these technologies in the future. The report is highly topical due to the controversy surrounding the ruling of the European Court of Justice on CRISPR/Cas9 genome…

    https://www.gesundheitsindustrie-bw.de/en/article/news/stocktaking-and-recommendations-for-action-the-bbaws-fourth-gene-technology-report
  • Press release - 10/12/2018 Trumpp_Andreas.jpg

    High distinction for stem cell researcher Andreas Trumpp

    This year's State Research Prize of Baden-Württemberg awarded for outstanding achievements in applied research goes to Andreas Trumpp from the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM). Theresia Bauer, State Minister of Science, Research and the Arts, presented the award, which carries a monetary prize of €100.000, at a festive ceremony on December 10, 2018.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-distinction-for-stem-cell-researcher-andreas-trumpp
  • Press release - 29/11/2018

    Hattrick in Freiburg

    Three researchers at the MPI for Immunobiology and Epigenetics receive millions in funding from the European Research Council. Dominic Grün, Nicola Iovino and Ritwick Sawarkar from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg will each be awareded one of the prestigious Consolidator Grants of the European Research Council. This means that 6 million euros in funding will go to fundamental research in Freiburg over the next…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hattrick-in-freiburg
  • Expert interview - 17/10/2018 Porträtfoto von Dr. Ralf Schumacher

    Biologicals are becoming increasingly important to Boehringer Ingelheim

    Biopharmaceuticals are playing an increasingly important role in Boehringer Ingelheim’s development pipeline. Visible evidence of this is the company’s Biologicals Development Centre (BDC) that is currently being constructed in Boehringer Ingelheim’s Biberach plant and will bring the company’s process development under one roof by early 2020. Walter Pytlik from BIOPRO talked with Dr. Ing. Ralf Schumacher about the new centre.

    https://www.gesundheitsindustrie-bw.de/en/article/news/biologicals-are-becoming-increasingly-important-to-boehringer-ingelheim
  • Article - 10/10/2018 Eine Frau, die sich das schildkrötenförmige weiß-blaue Gerät an die Brust drückt.

    BABYBE GmbH: Premature babies in contact with mum around the clock

    It used to be believed that premature babies needed as much rest as possible. However, studies have since shown that this is not the case at all. According to these studies, the brains of premature babies need to be stimulated 24 hours a day, ideally close to the mother, to ensure healthy development. The Stuttgart-based start-up BABYBE GmbH has developed a special gel mattress that enables babies to perceive their mother’s heartbeat and voice…

    https://www.gesundheitsindustrie-bw.de/en/article/news/babybe-gmbh-premature-babies-in-contact-with-mum-around-the-clock
  • Press release - 27/09/2018

    Three new Clusters of Excellence for Tübingen

    University takes next hurdle in the German government’s Excellence Strategy funding program. The University of Tübingen is to have three new Clusters of Excellence.As part of the German government’s Excellence Strategy funding forhigher education research, Tübingen will host new outstanding research networks starting in January 2019. Representatives of Germany’s higher education policymakers announced the decision in Bonn on Thursday.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/three-new-clusters-of-excellence-for-tuebingen
  • Cancer immunotherapy - 06/09/2018 Schematic showing the so-called breakthrough event as well as the expansion and invasion stages of cells during carcinogenesis.

    The immunogenicity of tumours and the development of new cancer medicines

    Microsatellite-unstable cancers are characterised by a large number of mutations within short repetitive DNA sequence regions, and can form novel peptides that the human immune system recognises as neoantigens. These cancers represent a starting point for the development of vaccines to prevent them appearing at an early stage of development. Microsatellite instability is particularly frequent in colon and cervical cancers.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-immunogenicity-of-tumours-and-the-development-of-new-cancer-medicines
  • Dossier - 28/08/2018 Woman wearing a white lab coat in a laboratory looking at a tube she is holding in her hand.

    With molecular diagnostics to biomarker-based personalised therapy

    Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy
  • Press release - 27/08/2018

    Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets

    Affimed will receive $96 million upfront and committed funding and is eligible for up to an additional $5.0 billion including milestone payments, and royalties on sales.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/affimed-announces-collaboration-with-genentech-to-develop-novel-nk-cell-engager-based-immunotherapeutics-for-multiple-cancer-tar
  • Article - 21/08/2018 Cells stained blue and red.

    Parkinson's disease: vitamin B3 has a positive effect on nerve cells

    Parkinson's disease is one of the most common neurodegenerative diseases in the world. There are around 4.1 million sufferers worldwide. It is characterised by motor impairments that result from the death of certain nerve cells in the brain. Researchers at the University of Tübingen have now discovered that vitamin B3 has a positive effect on damaged nerve cells and can boost their energy metabolism.

    https://www.gesundheitsindustrie-bw.de/en/article/news/parkinsons-disease-vitamin-b3-has-a-positive-effect-on-nerve-cells
  • Expert interview - 08/08/2018 Das Bild zeigt das Brustbild des ALS-Forschers, und Ärztlichen Direktors der Neurologischen Klinik der Uni Ulm, Prof. Albert Ludolph. Der Neurologe ist Sprecher des DZNE-Standorts Ulm.

    Ludolph: diagnosing and treating neurodegenerative disorders

    Ulm has long been a world leader in diagnosing and treating rare neurological disorders, notably amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Huntington's disease (HD). We spoke with Professor Albert C. Ludolph, spokesperson for the Ulm DZNE site, medical director of the Clinic for Neurology at the RKU (University and Rehabilitation Clinics of Ulm) and world-renowned ALS researcher.

    https://www.gesundheitsindustrie-bw.de/en/article/news/ludolph-diagnosing-and-treating-neurodegenerative-disorders
  • Company profile - 31/07/2018 Photo of the physicist.

    Acousia Therapeutics: medicines for deafness

    Deafness is one of the most common sensory disorders in the world: in Germany alone, around eleven million people suffer from hearing loss. So far there is no real therapy, the symptoms can only be alleviated to a greater or lesser degree. This is what researchers from the Tübingen-based company Acousia Therapeutics want to change: they have identified drug candidates that can protect sensory hair cells and support their function.

    https://www.gesundheitsindustrie-bw.de/en/article/news/acousia-therapeutics-medicines-for-deafness
  • Company profile - 26/07/2018 Screenshot of the pneumonia evid.one app.

    evid - therapy recommendations at a glance

    There are over 700 treatment guidelines in Germany alone, and each is up to several hundred pages long. Can doctors still stay on top of things? A start-up company from Mannheim called evid is developing a software that can retrieve relevant therapy recommendations for individual patients from the huge pile of paperwork. In March 2018, the founding trio won first place of the eHealthForum Freiburg start-up competition.

    https://www.gesundheitsindustrie-bw.de/en/article/news/evid-therapy-recommendations-at-a-glance
  • Press release - 04/07/2018 The collagen membrane „Collagen Cell Carrier“ is thin, elastic, yet robust and biocompatible.

    Phase-I-trial approved for novel stem cell therapy for patients with ischemic cardiomyopathy

    Viscofan BioEngineering, the biomedical business unit of the world market leader for collagenous sausage casings Viscofan announced today that the Spanish Agency for Medicines (AEMPS) has given green light to carry out a clinical phase-I-trial with Viscofan BioEngineering’s first product for regenerative medicine. The novel therapy consisting of stem cells on a collagenous carrier membrane can now be tested on ten patients suffering from severe…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/phase-i-trial-approved-for-novel-stem-cell-therapy-for-patients-with-ischemic-cardiomyopathy
  • Expert interview - 26/06/2018 Photo of Dr. med. Dr. rer. nat. Saskia Biskup.

    Genome analyses: "Germany lags behind dramatically"

    Around 6,000 genetic diseases can be diagnosed using genetic tests. Genetic testing enables the accurate identification of diseases especially when symptoms are unclear, and also allows statements to be made about disease progression. However, restrictive regulations considerably hinder the use of genetic diagnostics. BIOPRO spoke with Dr. Dr. Saskia Biskup, a human genetics specialist and co-founder of the Tübingen-based company CeGaT.

    https://www.gesundheitsindustrie-bw.de/en/article/news/genome-analyses-germany-lags-behind-dramatically
  • Article - 06/06/2018 Der Roboter ist modular aufgebaut und kann so für verschiedene Anwendungen genutzt werden.

    Robots for assisting with care and treatment in nursing homes and hospitals

    Robotic systems have great potential in the healthcare sector. For example, intelligent care aids, such as robotic technologies, extended care trolleys and lifters make life easier for nursing home and hospital staff. Mobile robots that assist with transport tasks or guiding people can help patients become more independent.

    https://www.gesundheitsindustrie-bw.de/en/article/news/robots-for-assisting-with-care-and-treatment-in-nursing-homes-and-hospitals
  • Article - 29/05/2018 Cells stained with a green fluorescing dye, on a computer keyboard.

    ITAS – Assessing the impact of life science technologies

    The Karlsruhe Institute for Technology Assessment and Systems Analysis (ITAS) is one of the largest and most renowned institutions in Germany involved in evaluating scientific and technological developments. The institute assesses the impacts and possible effects of new methods from a wide range of scientific fields - including the life sciences.

    https://www.gesundheitsindustrie-bw.de/en/article/news/assessing-the-impact-of-life-science-technologies
  • Article - 23/05/2018 Electron microscope image of a bacteriophage.

    Bacteriophages as alternatives to antibiotics

    Multidrug-resistant bacteria are resistant to many existing antibiotics and can be difficult to treat. There are increasing numbers of them worldwide. Although novel antibiotics are being developed, there are far too few of them to tackle the rise of multidrug-resistant bacteria. In Eastern Europe, doctors have been treating bacterial infections with viruses that infect bacteria, so-called bacteriophages, for almost 100 years.

    https://www.gesundheitsindustrie-bw.de/en/article/news/bacteriophages-as-alternatives-to-antibiotics

Page 5 / 29

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 29
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2022
Website address: https://www.gesundheitsindustrie-bw.de/en/search